For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 20,320 | 22,954* | 15,050 | 8,469 |
| Research and development - related party | 150 | 150* | 150 | 150 |
| General and administrative | 1,969 | 3,196* | 3,183 | 2,960 |
| Total operating expenses | 22,439 | 26,299 | 18,383 | 11,579 |
| Loss from operations | -22,439 | -26,299* | -18,383 | -11,579 |
| Interest income | - | 679* | - | - |
| Other income, net | 676 | -99* | 701 | 330 |
| Total other income, net | - | 580* | - | - |
| Net loss before taxes | -21,763 | -25,719* | - | - |
| Income tax expense | 373 | 259* | - | - |
| Net loss | -22,136 | -25,978 | -17,682 | -11,249 |
| Basic EPS | -1.24 | -1.178* | -0.99 | -0.96 |
| Diluted EPS | -1.24 | -1.178* | -0.99 | -0.96 |
Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc. (FBRX)